At present, the standard frontline therapy of steroids for graft versus host disease (GvHD) has shown to be ineffective for many patients. Now, speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Katie Gatwood, PharmD, BCOP, of Vanderbilt University Medical Center, Nashville, TN, provides an interesting update on the use of ibrutinib or ruxolitinib for the treatment GvHD. Dr Gatwood gives an insight on current studies that are investigating the use of ruxolitinib for acute and chronic GvHD, with the hope of ruxolitinib becoming FDA approved in the future.
Ruxolitinib and ibrutinib: the future for GvHD treatment?
